|
|
Blood, 15 February 2006, Vol. 107, No. 4, pp. 1570-1581.
Prepublished online as a Blood First Edition Paper on October 25, 2005; DOI 10.1182/blood-2005-06-2219.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia
Yubin Ge,
Alan A. Dombkowski,
Katherine M. LaFiura,
Dana Tatman,
Ravikiran S. Yedidi,
Mark L. Stout,
Steven A. Buck,
Gita Massey,
David L. Becton,
Howard J. Weinstein,
Yaddanapudi Ravindranath,
Larry H. Matherly, and
Jeffrey W. Taub
From the Experimental and Clinical Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Institute of Environmental Health Sciences, Wayne State University, Detroit, MI; Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI; Department of Pediatrics and Pharmacology, Wayne State University School of Medicine, Detroit, MI; Medical College of Virginia, Richmond, VA; University of Arkansas, Little Rock, AR; and Massachusetts General Hospital, Boston, MA.
Children with Down syndrome (DS) with acute megakaryocytic leukemia (AMkL) have very high survival rates compared with non-DS AMkL patients. Somatic mutations identified in the X-linked transcription factor gene, GATA1, in essentially all DS AMkL cases result in the synthesis of a shorter (40 kDa) protein (GATA1s) with altered transactivation activity and may lead to altered expression of GATA1 target genes. Using the Affymetrix U133A microarray chip, we identified 551 differentially expressed genes between DS and non-DS AMkL samples. Transcripts for the bone marrow stromal-cell antigen 2 (BST2) gene, encoding a transmembrane glycoprotein potentially involved in interactions between leukemia cells and bone marrow stromal cells, were 7.3-fold higher (validated by real-time polymerase chain reaction) in the non-DS compared with the DS group. Additional studies confirmed GATA1 protein binding and transactivation of the BST2 promoter; however, stimulation of BST2 promoter activity by GATA1s was substantially reduced compared with the full-length GATA1. CMK sublines, transfected with the BST2 cDNA and incubated with HS-5 bone marrow stromal cells, exhibited up to 1.7-fold reduced cytosine arabinoside (ara-C)-induced apoptosis, compared with mock-transfected cells. Our results demonstrate that genes that account for differences in survival between DS and non-DS AMkL cases may be identified by microarray analysis and that differential gene expression may reflect relative transactivation capacities of the GATA1s and full-length GATA1 proteins.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Up and down in Down syndrome: AMKL
- John D. Crispino
Blood 2006 107: 1251-1252.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
H. Edwards, C. Xie, K. M. LaFiura, A. A. Dombkowski, S. A. Buck, J. L. Boerner, J. W. Taub, L. H. Matherly, and Y. Ge
RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia
Blood,
September 24, 2009;
114(13):
2744 - 2752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Xavier, Y. Ge, and J. W. Taub
Down Syndrome and Malignancies: A Unique Clinical Relationship: A Paper from the 2008 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn.,
September 1, 2009;
11(5):
371 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Stankiewicz and J. D. Crispino
ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells
Blood,
April 2, 2009;
113(14):
3337 - 3347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Malinge, S. Izraeli, and J. D. Crispino
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome
Blood,
March 19, 2009;
113(12):
2619 - 2628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Rabin and J. A. Whitlock
Malignancy in Children with Trisomy 21
Oncologist,
February 1, 2009;
14(2):
164 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Elagib, I. S. Mihaylov, L. L. Delehanty, G. C. Bullock, K. D. Ouma, J. F. Caronia, S. L. Gonias, and A. N. Goldfarb
Cross-talk of GATA-1 and P-TEFb in megakaryocyte differentiation
Blood,
December 15, 2008;
112(13):
4884 - 4894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-H. Klusmann, U. Creutzig, M. Zimmermann, M. Dworzak, N. Jorch, C. Langebrake, A. Pekrun, K. Macakova-Reinhardt, and D. Reinhardt
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
Blood,
March 15, 2008;
111(6):
2991 - 2998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Blasius, E. Giurisato, M. Cella, R. D. Schreiber, A. S. Shaw, and M. Colonna
Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation.
J. Immunol.,
September 1, 2006;
177(5):
3260 - 3265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Bourquin, A. Subramanian, C. Langebrake, D. Reinhardt, O. Bernard, P. Ballerini, A. Baruchel, H. Cave, N. Dastugue, H. Hasle, et al.
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling
PNAS,
February 28, 2006;
103(9):
3339 - 3344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
